Ligand Initiates Clinical Trial with the Selective Androgen Receptor Modulator LGD-4033, a Potential Treatment of Muscle and Bone Disorders June 17, 2009
Ligand Pharmaceuticals and The Rockefeller University Enter Settlement Agreement and Mutual Release February 12, 2009
Ligand Earns $1 Million Milestone Payment on Progress of Drug Candidate for Alzheimer's Disease February 9, 2009
Ligand Enters into Exclusive License Agreement with GlaxoSmithKline to License Rights to LGD-4665 and other Ligand Thrombopoietin (TPO) Molecules December 18, 2008
Ligand Presents Positive LGD-4665 Clinical Trial Results at the American Society of Hematology Annual Meeting December 8, 2008